Skip to main content

Table 2 Assessment of patients’ quality of life

From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

  Group A (n= 58) Group B (n= 36) P value
Functional scales, mean ± SD    
Physical status 69.5 ± 31.3 67.8 ± 33.4 NS
Working ability 58.6 ± 40.1 55.4 ± 42.2 NS
Cognitive functioning 67.5 ± 34.8 66.1 ± 36.6 NS
Emotional functioning 62.3 ± 38.6 59.4 ± 28.5 NS
Social functioning 58.1 ± 32.5 53.3 ± 39.7 NS
Global quality of life 61.9 ± 33.3 51.7 ± 37.0 NS
Symptom scales, mean ± SD    
Fatigue 48.9 ± 32.1 68.1 ± 36.3 P < 0.05
Nausea and vomiting 26.8 ± 20.4 53.7 ± 32.6 P < 0.05
Pain 36.2 ± 28.5 34.2 ± 30.9 NS
Dyspnea 22.0 ± 27.9 32.2 ± 22.8 NS
Insomnia 55.7 ± 38.7 61.1 ± 41.7 NS
Appetite loss 33.3 ± 36.1 43.3 ± 39.1 NS
Constipation 23.8 ± 31.8 26.4 ± 30.4 NS
Diarrhea 21.0 ± 22.6 53.9 ± 38.5 P < 0.05
Financial difficulties 52.3 ± 37.3 58.8 ± 40.4 NS
Pancreas-specific pain 44.4 ± 29.2 49.5 ± 36.6 NS
Diet restriction 42.5 ± 32.0 54.1 ± 37.8 NS
Jaundice and pruritus 12.7 ± 20.1 18.8 ± 19.9 NS
Steatorrhea 36.1 ± 30.4 39.1 ± 34.7 NS
Poor body image 38.3 ± 34.2 59.8 ± 35.0 NS
Sexual dysfunction 66.8 ± 35.8 75.3 ± 41.1 NS
Dissatisfaction with care 61.2 ± 37.7 65.6 ± 39.1 NS
Bloating 41.7 ± 31.5 49.7 ± 37.4 NS
Bad-tasting food 29.4 ± 36.9 37.4 ± 38.2 NS
Indigestion 30.7 ± 30.1 39.5 ± 28.6 NS
Flatulence 35.7 ± 31.5 38.0 ± 32.3 NS
Difficulty gaining weight 49.5 ± 34.4 67.7 ± 40.5 P < 0.05
Weakness 45.9 ± 32.8 56.6 ± 42.7 NS
Dry mouth 40.5 ± 38.0 49.1 ± 36.9 NS
Treatment side-effects 39.1 ± 30.5 46.2 ± 33.8 NS
Worry about future 57.8 ± 35.8 66.3 ± 27.6 NS
Difficulty planning 34.6 ± 33.7 46.8 ± 45.2 NS
  1. SD standard deviation; NS no significant difference.